“Patients’ Quality of Life in a Phase 4 Real-World Study of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis”. 2023. SKIN The Journal of Cutaneous Medicine 7 (2): s135. https://doi.org/10.25251/skin.7.supp.135.